-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

4836 Unleashing the Power of CD19 CAR-T in Relapsed AML: Findings from a Prospective Single-Center Clinical Trial

Program: Oral and Poster Abstracts
Session: 704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster III
Hematology Disease Topics & Pathways:
Research, Clinical trials, Clinical Research
Monday, December 9, 2024, 6:00 PM-8:00 PM

Jia Yin1*, Qingya Cui1*, Haiping Dai2*, Zheng Li, MD1*, Liqing Kang3*, Wei Cui1*, Xiaopeng Tian1*, Xiaming Zhu1*, Lei Yu3*, Depei Wu, MD, PhD1 and Xiaowen Tang1*

1National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China
2The first Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, National Clinical Research Center of Hematologic Diseases, Suzhou, China
3Shanghai Unicar-Therapy Bio-Medicine Technology Co.,Ltd, Shanghai, China

Purpose: The relapsed t(8;21)(q22;q22.1) acute myeloid leukemia (AML) patients face an unfavorable prognosis and limited therapeutic options. To address this challenge, we evaluated the efficacy and safety of CD19 chimeric antigen receptor T-cell (CAR-T) therapy in these patients. Our recent retrospective study first reported favorable responses in two patients with t(8;21) AML, indicating significant progress in this field []. This prospective single-center clinical trial aimed to assess further the safety and efficacy of CD19 CAR T-cell therapy in CD19-positive relapsed t(8;21)(q22;q22.1) AML patients.

Methods: Ten relapsed CD19-positive t(8;21) AML patients were enrolled in this trial (NCT03896854). Following tumor reduction chemotherapy, all patients received a dose-escalated infusion of 5-20 ×106 CD19 CAR-T cells/kg after lymphodepletion chemotherapy with cyclophosphamide (300 mg/m² for 3 days) and fludarabine (30 mg/m² for 3 days) from days -5 to -3. The dose distribution was 10%, 30%, and 60% over three days. Primary endpoints included hematologic toxicities, non-hematological toxicities, and CAR-T-related side effects, while secondary endpoints were complete remission rate, overall survival (OS) and leukemia-free survival (LFS).

Results: The cohort comprised ten patients (8 males, 2 females) aged 13 to 52 (median age 31). The median CD19 expression in AML blasts was 52.8% (22.6%-97.1%). Hematologic relapses were observed in eight patients, with molecular relapses in two. Two patients relapsed post-allogeneic transplantation. Notably, adverse mutations in the KIT and TP53 genes were identified in the other two patients with multiple relapses (Patients 2 and 3, respectively). As of April 2024, the median follow-up duration was 11.6 months (3.0-76.9 months). In our study of ten patients with relapsed t(8;21) AML, CD19 CAR T-cell therapy demonstrated a high safety profile and efficacy. Grade 3 neutropenia or thrombocytopenia toxicity was observed in three patients and grade 4 in seven patients. The median time for neutrophil recovery was 12 days (1 to 24 days), and 14 days (0 to 30 days) for platelet recovery. Non-hematological toxicities were mild, including fever in three patients, grade 1 liver dysfunction, and hypertension in one patient. Cytokine release syndrome (CRS) was observed in nine patients, with only one case of grade 3 severity managed successfully with steroids. The therapy achieved a 100% response rate, with 60% of patients attaining molecular MRD-negative complete remission and the remainder achieving hematologic complete remission, with a 12-month OS rate of 45.0% and a 12-month LFS of 46.7%. Nonetheless, relapse, predominantly characterized by CD19-negative phenotypes, was a common occurrence within six months post-treatment.

Conclusion: CD19 CAR T-cell therapy is a promising and manageable treatment for relapsed CD19-positive t(8;21) AML, offering a potential new strategy for disease remission with a manageable safety profile. It also highlights the importance of maintenance therapy in sustaining remission and improving long-term outcomes.

[1] Qu C, Li Z, Kang L, Wang Y, Dai H, Yin J, et al. Successful treatment of two relapsed/refractory t(8;21) acute myeloid leukemia patients by CD19-directed chimeric antigen receptor T cells. Bone Marrow Transplant. 2019;54:1138-40.

Disclosures: No relevant conflicts of interest to declare.

*signifies non-member of ASH